This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects
Inclusion Criteria:
Exclusion Criteria:
AteaClinicalTrials@ateapharma.com
AT-587 administered orally, dose 1 on Day 1
Matching placebo dose 1 administered orally on Day 1
AT-587 administrated orally, dose 2 on Day 1 and Day 7
Matching placebo dose 2 administered orally on Day 1 and Day 7
AT-587 administered orally, dose 3 on Day 1
Matching placebo dose 3 administered orally on Day 1
AT-587 administered orally, dose 4 on Day 1
Matching placebo dose 4 administered orally on Day 1
AT-587 - administered orally, dose 5 (QD) for 7 days
Matching placebo dose 5 administered orally once daily (QD) for 7 days
AT-587 administered orally, dose 6 daily split (BID) for 7 days
Matching placebo administered orally dose 6 daily split (BID) for 7 days
AT-587 administered orally, dose 7 (QD) or split (BID) for 7 days
Matching placebo administered orally, dose 7 daily (QD) or split (BID) for 7 days
Study of AT-752 in Healthy Subjects
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
Study of AT-527 in Healthy Subjects (R07496998)
A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection
A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants
Study of AT-527 in Healthy and HCV-Infected Subjects
Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal
Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117